SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy.

TitleSNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy.
Publication TypeJournal Article
Year of Publication2023
AuthorsHope TA, Antonarakis ES, Bodei L, Calais J, Iravani A, Jacene H, Koo PJ, Morgans AK, Osborne JR, Tagawa ST, Taplin M-E, Sartor O, Morris MJ
JournalJ Nucl Med
Volume64
Issue9
Pagination1417-1423
Date Published2023 Sep
ISSN1535-5667
KeywordsDipeptides, Heterocyclic Compounds, 1-Ring, Humans, Lutetium, Male, Patient Selection, Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant, Radioisotopes
DOI10.2967/jnumed.123.265952
Alternate JournalJ Nucl Med
PubMed ID37290800
Related Institute: 
Molecular Imaging Innovations Institute (MI3)

Weill Cornell Medicine
Department of Radiology
525 East 68th Street New York, NY 10065